UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037950
Receipt number R000043259
Scientific Title A study for evaluating the effect of the test food on relating nasal and ocular symptoms in an environmental exposure unit (EEU)
Date of disclosure of the study information 2019/09/06
Last modified on 2020/03/06 09:43:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study for evaluating the effect of the test food on relating nasal and ocular symptoms in an environmental exposure unit (EEU)

Acronym

A study for evaluating the effect of the test food on relating nasal and ocular symptoms in an environmental exposure unit (EEU)

Scientific Title

A study for evaluating the effect of the test food on relating nasal and ocular symptoms in an environmental exposure unit (EEU)

Scientific Title:Acronym

A study for evaluating the effect of the test food on relating nasal and ocular symptoms in an environmental exposure unit (EEU)

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of the test food on nasal and ocular symptoms

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Record during pollen exposure
(the number of sneezes and nose blowing, visual analog scale of nasal blockage, nasal itching, eye itching, watery eyes, throat symptoms, sleepiness and daily life)

Key secondary outcomes

Record after exposure pollen
(the number of sneezes and nose blowing, visual analog scale of nasal blockage, nasal itching, eye itching, watery eyes , throat symptoms, sleepiness, and daily life)
visual analog scale of awaking.
eosinophil of nasal mucus.
Doctor observation of the nasal mucus and the nose


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake I period (test food) - washout period - Intake II period (placebo)

Interventions/Control_2

Intake I period (placebo) - washout period - Intake II period (test food)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

69 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Males and females from 20 to 69 years of age
(2) Subjects who complained of nasal and ocular symptoms and judged.
(3) Subjects who are judged as suitable for the study by the investigator.
(4) Subjects who obtained the consent about participation in the study.
(5) Subjects who do not take antiallergic drug account for more than half of whole.

Key exclusion criteria

(1) Subjects who constantly use health food richly containing involvement ingredient
(2) Subjects who routinely take medicine affecting the test result.
(3) Subjects who have severe nasal and eye symptoms affecting judgement of symptoms
(4) Subjects who have a medical treatment (specific desensitization therapy) which may influence the outcome of the study.
(5) Subjects who are engaged in drive a car or operate a hazardous machine.
(6) Subjects judged as unsuitable for the study by the investigator for laboratory evidence or cardiopulmonary function.
(7) Subjects who have a disease requiring regular medication or a history of serious disease for which medication was required.
(8) Subjects who are liable to cause an allergy related to the study.
(9) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination.
(10) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire.
(11) Subjects who have participated in other clinical studies at the time of this study start
(12) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating.
(13) Subjects who are judged as unsuitable for the study by the investigator for other reason.

Target sample size

22


Research contact person

Name of lead principal investigator

1st name Eri
Middle name
Last name Saito

Organization

Asama Chemical. Co., Ltd.

Division name

Laboratory

Zip code

103-0001

Address

20-6, Nihonbashikodenmacho, Chuo-ku, Tokyo

TEL

03-3661-6282

Email

saito@asama-chemical.co.jp


Public contact

Name of contact person

1st name Chiharu
Middle name
Last name Goto

Organization

TTC Co., Ltd.

Division name

Clinical Research Planning Department

Zip code

150-0021

Address

Seibu Shinkin Bank Ebisu Bldg,1-20-2, Ebisunishi, Shibuya-ku, Tokyo

TEL

03-5459-5329

Homepage URL


Email

c.goto@ttc-tokyo.co.jp


Sponsor or person

Institute

TTC Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

Asama Chemical. Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

FURUKAWA Research & Consulting

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aisei Hospital Ueno Clinic Research Ethics Committee

Address

2-18-6, Higashiueno, Taitou-ku, Tokyo

Tel

03-6455-0880

Email

t.saito@ttc-smo.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 09 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 22 Day

Date of IRB

2019 Year 08 Month 22 Day

Anticipated trial start date

2019 Year 09 Month 07 Day

Last follow-up date

2019 Year 10 Month 23 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 06 Day

Last modified on

2020 Year 03 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043259


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name